CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer.
Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participant must have relapsed, recurrent or refractory synovial sarcoma
-Participant must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at time of enrollment
-Participant must have received at least one line of prior systemic treatment at the time of enrollment
-Participant must have adequate organ function, including blood, blood clotting, liver, kidney, heart and blood pressure control
-Participant must not be a candidate for surgical tumor removal at the time of enrollment
-Participant must not have had already taken ramucirumab
-Participant must not have previously progressed on the combined regimen of gemcitabine/docetaxel and must not have known allergies to any of the agents in the regimen
-Participant must not be at risk for and/or have history of serious bleeding or blood clot events; heart problems; blood pressure crises or brain disease; stomach or liver problems; fistulas, ulcers or perforations, or abdominal abscesses; non-healing wounds or broken bones
-Participant must not have symptomatic or radiologic findings of interstitial pneumonia or pulmonary fibrosis